EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Asker Healthcare (ASKER) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Asker Healthcare SEK 28.26, price SEK 60.90, upside -53.6%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SE · ISIN SE0024171458

AH Broad data Sep 24, 2026

Asker Healthcare

ASKER · ST

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value kr 28.26 · Strongly overvalued (−54%)
!Quality 52/100
✓Healthy Growth (revenue 3y +12.7 %/yr)
!Thin margins · 3.4% net margin (TTM)
✓Moderate debt · generates free cash flow
·0.64% dividend yield
!Mixed vs. peers (6/14)
!Narrow moat 41/100
!Insider activity 40/100
!Weak on dividend: 13 out of 100
Watch Asker Healthcare for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 130.59 kr 56.65 Fair Value kr 28.26 Mar 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

18‑month range kr 56.65 – kr 130.59 · fair‑value band kr 20.72 – kr 35.32 · the kr 60.90 price screens above the kr 28.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Asker Healthcare in your weekly email

Every Wednesday you see whether Asker Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care.

Show more

Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care. The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products. In addition, it develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services. Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; and products for physiotherapy practices, as well as supplies exercise and treatment equipment and measurement. Additionally, it sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products. The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland. Asker Healthcare Group AB (publ) was founded in 2006 and is headquartered in Danderyd, Sweden.

Stock analysis

Asker Healthcare (ASKER) currently trades at kr 60.90, while our model-based Fair Value estimate is kr 28.26, implying the stock looks roughly 115.5% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of kr 45.42 per share, and 5 of the 24 models we run sit above the kr 60.90 price.

Bear case: the Asset-Based group reads lowest at kr 11.47, and 19 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: kr 20.72 (bear) to kr 35.32 (bull), the price of kr 60.90 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Asker Healthcare reported revenue of 16.8B SEK in FY2025 versus 9.4B SEK in FY2021, a compound +15.7%/yr. Reported net income was 492M SEK in FY2025, compounding +1.3%/yr from FY2021.

Key figures

Market cap 30.4B SEK (≈ $3.1B) · P/E ratio 39.0 · P/S ratio 1.14 · EPS (TTM) kr 1.56 · Dividend yield 0.6% · Net margin 2.9% · Return on equity 9.3% · Return on assets (EBIT) 6.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 35% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 42% fair-value upside, at −54%, ASKER screens richer than that median.

Fair Value models

Bear kr 20.72 Fair Value kr 28.26 Bull kr 35.32
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.8559 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV kr 12.67 kr 16.23 kr 19.35 74
FCF DCF kr 33.68 kr 70.53 kr 136.41 72
Growth DCF kr 33.14 kr 66.36 kr 123.77 71
All 24 models by family
DCF Models
FCF DCF kr 33.68 kr 70.53 kr 136.41 72
Owner Earnings kr 32.99 kr 69.24 kr 134.05 69
5Y Revenue Exit kr 21.00 kr 41.74 kr 69.79 67
5Y EBITDA Exit kr 36.50 kr 74.36 kr 122.62 69
5Y P/E Exit kr 18.14 kr 35.72 kr 55.73 66
10Y Revenue Exit kr 24.03 kr 45.42 kr 78.19 61
10Y EBITDA Exit kr 35.24 kr 69.59 kr 123.28 62
10Y P/E Exit kr 22.96 kr 40.96 kr 66.19 59
Earnings-Based
Graham-Dodd kr 8.73 kr 43.35 kr 59.80 61
Lynch FV kr 11.70 kr 16.71 kr 21.72 58
PEG = 1.0 kr 11.70 kr 16.71 kr 21.72 55
EPV kr 12.67 kr 16.23 kr 19.35 74
Multiples
P/E Multiple kr 21.19 kr 28.26 kr 35.32 63
P/S Multiple kr 16.38 kr 21.84 kr 27.30 58
P/B Multiple kr 16.38 kr 21.84 kr 27.30 55
EV/EBIT kr 24.87 kr 36.06 kr 47.26 65
EV/EBITDA kr 41.31 kr 57.99 kr 74.66 67
EV/Revenue kr 15.25 kr 25.53 kr 35.80 52
Asset-Based
NCAV (Graham) kr 8.56 kr 11.47 kr 17.11 54
Growth DCF
Growth DCF kr 33.14 kr 66.36 kr 123.77 71
Rev-Margin DCF kr 21.00 kr 41.38 kr 68.33 67
Economic Profit
Residual Income kr 14.07 kr 14.94 kr 16.44 68
ROIC Compounder kr 12.67 kr 16.23 kr 22.57 68
Growth Earnings
Growth-Adj P/E kr 18.39 kr 26.28 kr 34.16 65

Open the full fair value analysis →

Notify me when ASKER reaches fair value

Put ASKER on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 52/100

Of which business quality 53 · Market factors (momentum, volatility) 24

Profitability 48
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 34
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 98
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 82/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.8%
Dividend (yield on the price)0.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 6%

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +16.0% a year for the price and +5.8% for the forecasts.
Forecast 2026 (sales)+14.2%
Forecast 2027 (sales)+7.4%
Projected 2028 (sales)+6.7%
Projected 2029 (sales)+6.1%
Projected 2030 (sales)+5.4%

ASKER screens 116% overvalued. Compare with McKesson Corporation →

Compare Asker Healthcare with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Above median
Fair Value upside −52% · Bottom 25%
Profitability
Return on equity (TTM) 9% · Above median
Return on assets 5% · Top 25%
Net margin (TTM) 3% · Above median
Operating margin (TTM) 7% · Above median
Growth and dividend
Revenue growth 13% · Top 25%
Dividend yield (TTM) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.64× · Highest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 39.0× · Priciest 25%
P/B 4.64× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 1.76× · Priciest 25%
P/FCF 4.2× · Pricier than median
EV/EBITDA 19.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)66 · sector 18
PAST (return on equity)37 · sector 27
HEALTH (low debt)68 · sector 96
DIVIDEND (yield)13 · sector 59

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $891.23 $819.31 −8%
Cencora, Inc COR $314.43 $211.07 −33%
Cardinal Health, Inc CAH $222.04 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.04 ¥42.67 +166%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.68 ¥27.98 +42%
Jointown Pharmaceutical Group 600998 ¥4.87 ¥9.84 +102%
China National Medicines Corporation 600511 ¥26.12 ¥58.47 +124%
EBOS Group EBO A$15.69 A$22.40 +43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Asker Healthcare · Fair Value
kr 28.26 −116%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Asker Healthcare Fair Value". https://www.fairvalue-calculator.com/stock/ASKER

Frequently asked questions

Is Asker Healthcare (ASKER) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 28.26 versus a price of kr 60.90, about −54% upside (overvalued).
What is the fair value of ASKER?
Our model-based fair value for Asker Healthcare is kr 28.26 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 60.90.
What is the quality score of ASKER?
Asker Healthcare has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Asker Healthcare (ASKER)?
Our model-based price target is the fair value of kr 28.26 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 20.72, optimistic scenario kr 35.32. It is a calculation from audited fundamentals, not an analyst target.
What is the Asker Healthcare stock forecast for 2026?
Our models put fair value at kr 28.26, about −54% upside versus a price of kr 60.90 (overvalued). Cautious scenario kr 20.72, optimistic scenario kr 35.32. The calculation is refreshed regularly with new filings.
What is the revenue of Asker Healthcare (ASKER)?
Asker Healthcare reported trailing-twelve-month revenue of about 17.3B SEK (latest available figure, as of Sep 24, 2026).
Does Asker Healthcare pay a dividend?
Asker Healthcare currently shows a dividend yield of about 0.64% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Asker Healthcare (ASKER)?
For today's price to be fair in a discounted-cash-flow model, Asker Healthcare would have to grow free cash flow by +18.3 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +15.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ASKER use?
Our models discount Asker Healthcare at 9.0 %: a base by market capitalisation (large), country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Asker Healthcare that is +18.3 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Asker Healthcare (ASKER) delivered so far?
Over the past 4 years revenue at Asker Healthcare grew +15.7 % a year. The price currently implies +18.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Asker Healthcare (ASKER) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Asker Healthcare (+18.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Asker Healthcare (ASKER)?
The free-cash-flow yield on the price is 3.29 %: that much free cash flow Asker Healthcare produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Asker Healthcare (ASKER)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Asker Healthcare it is kr 28.26 per share (as of Sep 24, 2026), against a price of kr 60.90. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Asker Healthcare stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ASKER trades above its calculated fair value: price kr 60.90, fair value kr 28.26, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASKER?
No. The price is what the market pays today (kr 60.90); the fair value is what the company's own numbers justify (kr 28.26). For Asker Healthcare the two are kr 32.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is Asker Healthcare worth?
The market values Asker Healthcare at about 30.4B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 60.90; our models calculate a fair value of kr 28.26 per share.
What do the bullish and bearish scenarios say about ASKER?
Our models span a range for Asker Healthcare: cautious scenario kr 20.72, base kr 28.26, optimistic kr 35.32 per share (as of Sep 24, 2026, price kr 60.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ASKER?
Asker Healthcare trades at a price-to-earnings ratio of 39.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 28.26 is built from several models across several years. Other multiples: P/B 4.6, P/S 1.8, EV/EBITDA 19.9.
How solid is the balance sheet of Asker Healthcare (ASKER)?
Balance-sheet figures for Asker Healthcare (as of Sep 24, 2026): return on equity 9.3%, debt of 0.64 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is ASKER from its 52-week high?
Asker Healthcare trades at kr 60.90, about 35% below its 52-week high of kr 93.95 and 8% above the low of kr 56.65 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 28.26 is for.
Which stocks are comparable to Asker Healthcare?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Asker Healthcare stock attractive at the current price?
The data as of Sep 24, 2026: price kr 60.90, calculated fair value kr 28.26 (−54%), Quality Score 52/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASKER calculated?
We run Asker Healthcare through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 28.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Asker Healthcare itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Asker Healthcare (ASKER)?
The closing price on Sep 23, 2026 was kr 60.90. Our model-based fair value is kr 28.26, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Asker Healthcare right now?
The price sits above even our optimistic bull case (kr 35.32). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Asker Healthcare

How large is the market capitalisation of Asker Healthcare (ASKER)?
The market capitalisation of Asker Healthcare is 30.4B SEK (≈ $3.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Asker Healthcare (ASKER)?
The price-to-sales ratio of Asker Healthcare is 1.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Asker Healthcare (ASKER)?
Earnings per share at Asker Healthcare are kr 1.56 (price ÷ EPS = P/E 39.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Asker Healthcare (ASKER)?
The dividend yield of Asker Healthcare is 0.6% (payout 25.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Asker Healthcare (ASKER)?
The net margin of Asker Healthcare is 2.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Asker Healthcare (ASKER)?
The return on equity (ROE) of Asker Healthcare is 9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Asker Healthcare (ASKER)?
On an EBIT basis the return on assets of Asker Healthcare is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Asker Healthcare (ASKER)?
The operating margin of Asker Healthcare is 6.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Asker Healthcare (ASKER)?
Revenue at Asker Healthcare is growing +13.2% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Asker Healthcare (ASKER)?
Earnings per share at Asker Healthcare are growing +172% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Asker Healthcare (ASKER) carry?
The net debt of Asker Healthcare is 4.9B SEK (fiscal year 2025, ≈ 6.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Asker Healthcare in the live analysis

One click puts Asker Healthcare on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.